## 2014 EU-wide Stress Test

| Bank Name | DNB Pank AS |
| :---: | :---: |
| LEI Code | 213800JD2L89GGG7LF07 |

## 2014 EU-wide Stress Test

## Summary Adverse Scenario

DNB Pank AS

| Actual figures as of 31 December 2013 | min EUR, \% |
| :--- | :---: |
| Operating profit before impairments | 4 |
| Impairment losses on financial and non-financial assets in the banking book | 28 |
| Common Equity Tier 1 capital (1) | 69 |
| Total Risk Exposure (1) | 483 |
| Common Equity Tier 1 ratio, \% (1) | $\mathbf{1 4 . 2 \%}$ |


| Outcome of the adverse scenario as of 31 December 2016 | mln EUR, \% |
| :---: | :---: |
| 3 yr cumulative operating profit before impairments | 8 |
| 3 yr cumulative impairment losses on financial and non-financial assets in the banking book | 16 |
| 3 yr cumulative losses from the stress in the trading book | 0 |
| Valuation losses due to sovereign shock after tax and prudential filters | 0 |
| Common Equity Tier 1 capital (1) | 61 |
| Total Risk Exposure (1) | 514 |
| Common Equity Tier 1 ratio, \% (1) | 11.8\% |
| Memorandum items | min EUR |
| Common EU wide CET1 Threshold (5.5\%) | 28 |
| Total amount of instruments with mandatory conversion into ordinary shares upon a fixed date in the 2014-2016 period (cumulative conversions) (2) | 0 |
| Total Additional Tier 1 and Tier 2 instruments eligible as regulatory capital under the CRR provisions that convert into Common Equity Tier 1 or are written down upon a trigger event (3) | 0 |
| Of which: eligible instruments whose trigger is above CET1 capital ratio in the adverse scenario (3) | 0 |

(1) According to CRR/CRD4 definition transitional arrangements as per reporting date. Figures as of 31/12/2013 computed as of first day of application: 1/01/2014.
(2) Conversions not considered for CET1 computation
(3) Excluding instruments with mandatory conversion into ordinar shares upan a fxed date in the 2014 -2016 period

## 2014 EU-wide Stress Test

## Summary Baseline Scenario

DNB Pank AS

| Actual figures as of 31 December 2013 | mln EUR, \% |
| :--- | :---: |
| Operating profit before impairments | 4 |
| Impairment losses on financial and non-financial assets in the banking book | 28 |
| Common Equity Tier 1 capital (1) | 69 |
| Total Risk Exposure (1) | 483 |
| Common Equity Tier 1 ratio, \% (1) | $\mathbf{1 4 . 2 \%}$ |


| Outcome of the baseline scenario as of 31 December 2016 | mln EUR, \% |
| :--- | :---: |
| 3 yr cumulative operating profit before impairments | 12 |
| 3 yr cumulative impairment losses on financial and non-financial assets in the banking book | 8 |
| 3 yr cumulative losses from the stress in the trading book | 0 |
| Common Equity Tier 1 capital (1) | 72 |
| Total Risk Exposure (1) | 488 |
| Common Equity Tier 1 ratio, \% (1) | $\mathbf{1 4 . 8 \%}$ |

號 1 ratio, \% (1)

## Memorandum items

Common EU wide CET1 Threshold ( $8.0 \%$ ) min EUR
(1) According to CRR/CRD4 deffinition transitional arrangements as per reporting date. Figures as of 31/12/2013 computed as of first day of application 01/01/2014.


2014 EU-wide Stress Test



=asivat


## 2014 EU-wide Stress Test

P\&L
(mln EUR)
Net interest income
Net trading income
of which trading losses from stress scenarios
Other operating income
Operating profit before impairments
Impairment of financial assets (-)
Impairment of financial assets other than instruments designated at fair value throuah P\&L (-)
Impairment Financial assets designated at fair value through P\&L (-)
Impairment on non financial assets (-)
Operating profit after impairments from stress scenarios
Other Income and expenses
Pre-Tax profit
Tax
Net income
Attributable to owners of the parent
of which carried over to capital through retained earnings
of which distributed as dividends

| 31/12/2013 | Baseline Scenario |  |  | Adverse Scenario |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31/12/2014 | 31/12/2015 | 31/12/2016 | 31/12/2014 | 31/12/2015 | 31/12/2016 |
| 11 | 11 | 11 | $11$ | 11 | 10 | 9 |
|  | 0 | 0 | 0 | 0 | 0 | 0 |
|  | 0 | 0 | 0 | 0 | 0 | 0 |
| 0.499 | 0 | 1 | 1 | 0 | 1 | 1 |
| 4 | 4 | 4 | 4 | 4 | 3 | 2 |
| -27.991 | -3 | -2 | -2 | -4 | -5 | -7 |
| -27.991 | -3 | -2 | -2 | -4 | -5 | -7 |
|  | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -24 | 1 | 2 | 2 | 0 | -3 | -5 |
| 0.368 | 0 | 0 | 0 | 0 | 0 | 0 |
| -24 | 1 | 2 | $2$ | 0 | -3 | -5 |
| 0 | 0 | 0 | -1 | 0 | 0 | 0 |
| -24 | 1 | 1 | $1$ | 0 | -3 | -5 |
| -24 | 1 | 1 | 1 | 0 | -3 | -5 |
| -24 | 1 | 1 | 1 | 0 | -3 | -5 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |

In the figures above, the original (official published) 2013 P\&L figures may have been adjusted as part of the ECB Comprehensive Assessment join-up calculation.

2014 EU-wide Stress Test

| RWA |  | Baseline Scenario |  |  | Adverse Scenario |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | as of 31/12/2013 | as of 31/12/2014 | as of 31/12/2015 | as of 31/12/2016 | as of 31/12/2014 | as of 31/12/2015 | as of 31/12/2016 |
| Risk exposure amount for credit risk | 483 | 492 | 489 | 488 | 540 | 528 | 514 |
| Risk exposure amount Securitisation and re-securitisations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Risk exposure amount Other credit risk | 483 | 492 | 489 | 488 | 540 | 528 | 514 |
| Risk exposure amount for market risk | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Risk exposure amount for operational risk | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Transitional floors for Risk exposure amount | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AQR adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Risk exposure amount | 483 | 492 | 489 | 488 | 540 | 528 | 514 |

## 2014 EU-wide Stress Test

Securitisation

| Securitisation |  |  | Baseline scenario |  |  | Adverse scenario |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | (mln EUR) | as of 31/12/2013 | 31/12/2014 | 31/12/2015 | 31/12/2016 | 31/12/2014 | 31/12/2015 | 31/12/2016 |
| Exposure values | Banking Book <br> Trading Book (excl. correlation trading positions under CRM) Correlation Trading Portfolio (CRM) <br> Total | $\begin{aligned} & \hline 0 \\ & 0 \\ & 0 \\ & \mathbf{0} \\ & \hline \end{aligned}$ |  |  |  |  |  |  |
| Risk exposure values | Banking Book <br> Trading Book (excl. correlation trading positions under CRM) <br> Total | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & \mathbf{0} \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |
| Impairments | Hold to Maturity porfolio Available for Sale porfolio Held for trading portfolio Total |  | 0 0 | 0 0 | 0 0 0 | 0 0 0 | 0 0 0 | 0 0 0 |

2014 EU-wide Stress Test - Sovereign Exposure


2014 EU-wide Stress Test - Sovereign Exposure


2014 EU-wide Stress Test - Sovereign Exposure


2014 EU-wide Stress Test - Sovereign Exposure


2014 EU-wide Stress Test - Sovereign Exposure


| 2014 EU－wide Stress Test Capital |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Bascsine semario |  |  | Anverse Scenario |  |  |  | ееелйтои |
| （mne Eie） |  | cra／／crov deaminton or carital | Aso $1313121 / 2013$ |  |  |  |  <br> As of 31／12／2014 | Asot $31 / 12 / 20015$ |  |  |  |
| own funos | A | ownevus | ${ }^{\circ}$ | 7 | ＂ | 2 | ${ }^{\circ}$ | ${ }^{6}$ | ${ }^{\circ}$ | an（1） | Antase |
|  | ${ }_{\text {a }}$ |  | ${ }^{\circ}$ | $\%$ | $»$ | 2 | ${ }^{\circ}$ | ${ }^{\circ}$ | ${ }^{1}$ | aralily | Autesesoras |
|  | A．1． |  | ${ }^{12}$ | ${ }_{102}$ | ${ }^{12}$ | ${ }^{12}$ | 12 | ${ }^{12}$ | 128 | Catatali， |  |
|  | 11.11 |  | － | 。 | － | － | 。 | 。 | － |  |  |
|  | A12 | Resase eminios | 3 | ， | ${ }^{30}$ | ${ }^{28}$ | 3 | ${ }^{35}$ | $\pm 0$ | ca（1412） | （atemexitit |
|  | ${ }^{12}$ |  | － | 。 | 。 | 。 | － | － | － | Cax 11.13 ） |  |
|  | 4131 |  | 。 | 。 | 。 | 。 | 。 | 。 | － |  |  |
|  | ${ }^{1.32}$ |  | 。 | 。 | 。 | 。 | － | 。 | 。 |  |  |
|  | A14 | Orie Resens | － | 。 | 。 | 。 | － | － | $\cdots$ | catatine | Amesesturne |
|  | ${ }^{1.15}$ | ， | 。 | 。 | 。 | 。 | 。 | 。 | － | ca（1415） |  |
|  | ${ }^{\text {A1，}}$ |  | 。 | 。 | 。 | 。 | － | 。 | － | Cutanin） | anceseactar |
|  | ${ }^{\text {A17 }}$ | Nater | 。 | 。 | － | 。 | － | 。 | － | ca（14．19） |  |
|  | ${ }^{\text {a } 18}$ | （e） | 。 | 。 | 。 | 。 | － | － | － |  |  |
|  | ${ }^{\text {A1，}}$ |  | 1 | － | 1 | － | 1 | 1 | 1 | ${ }_{\text {a }}^{\text {and }}$ | 为 |
|  | A1．10 | （ta | 。 | 。 | 。 | － | 。 | 。 | － | catatilit |  |
|  | A1，11 | （9）Wes simetald cestit | 。 | － | － | 。 | － | － | $\bigcirc$ | anatalin） |  |
|  | ${ }^{\text {A1．12 }}$ |  | 。 | 。 | 。 | 。 | 。 | 。 | $\cdots$ | catatine |  |
|  | A1．3 |  | 。 | 。 | 。 | － | － | － | － |  |  |
|  | 41.14 |  | 。 | － | 。 | － | － | 。 | － | atatilite | mosesf（ ）ementocar |
|  | 1.15 | $(-)$ Deductions related to assets which can alternatively be subject to a $1.250 \%$ risk weight | － | － | － | － | － | － | － |  |  |
|  | ${ }^{\text {A．} 1.51}$ |  | 。 | 。 | 。 | 。 | 。 | 。 | － | auth11．as） |  |
|  | 1.16 |  | － | － | 。 | － | － | － | － | ${ }^{\text {ana }} 11.123$ |  |
|  | a1，17 |  | － | － | 。 | － | － | － | － | （1123 |  |
|  | ${ }^{\text {A1，18 }}$ |  | 。 | 。 | 。 | 。 | 。 | 。 | － | antilutice | （axtex |
|  | A1．19 |  | 。 | 。 | 。 | 。 | 。 | 。 | $\bigcirc$ | an（1．12，27） | Antesend crap |
|  | ${ }^{\text {A120 }}$ | Trasiona disismeneis | － | － | － | － | － | － | $\cdots$ |  |  |
|  | A1220 |  | 。 | 。 | 。 | 。 | 。 | 。 | $\cdots$ | Catatas） |  |
|  | ${ }^{\text {A1202 }}$ |  | － | 。 | － | 。 | － | 。 | － | Catatis） |  |
|  | 41.208 | （e） | 。 | 。 | 。 | 。 | 。 | 。 | － | Cutatilize |  |
|  | ${ }_{\text {A } 22}$ |  | $\bigcirc$ | － | － | － | － | 。 | － | Catalat | Amatesatarar |
|  | 421 |  | 。 | － | － | － | － | $\bigcirc$ | － |  |  |
|  | ${ }^{12}$ |  | ${ }^{\circ}$ | 70 | $\square$ | 7 | ${ }^{\circ}$ | ${ }^{6}$ | ${ }^{\circ}$ | ana | Auteres scar |
|  | 0.4 |  | － | － | － | － | － | $\bigcirc$ | $\bigcirc$ | an（12） | materictar |
| OWN FUNDSREQUIREMENTS | ${ }^{\text {B }}$ |  | 。 | $\stackrel{4}{6}$ | 4 | ${ }^{68}$ | som | ${ }_{58}$ | $\stackrel{59}{0}$ |  |  |
|  | ${ }_{6}^{61}$ | demen | ． | 。 | － | 。 | ： | ： | ： |  |  |
|  | ${ }^{8}$ |  | 。 | 。 | 。 | 。 | 。 | 。 | － |  | aneses speze ccar |
|  | ${ }^{8.4}$ |  | $\bigcirc$ | 。 | － | － | － | 。 | － |  | Resimemefar |
|  | ${ }^{4} 5$ |  | － | $\bigcirc$ | － | － | － | － | － |  |  |
|  | ${ }_{86} 8$ | ${ }^{\text {a }}$ | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ |  |  |
|  | $\mathrm{c}^{\text {c．}}$ | Common Equitiverer Capital rito | 14220\％ | 12．85\％ | ${ }^{1.55 \%}$ | 1，979\％ | 122\％ | 1254\％ | 1．39\％ | ${ }^{c} 3_{43}$ |  |
|  | ${ }^{\text {c．} 2}$ | Terat Cipitalatio | ${ }^{124220}$ | ${ }^{12.4586}$ | 1.455 | 14.976 | ${ }^{1222 \%}$ | ${ }^{12515}$ | 11.385 | casar |  |
|  | ${ }^{\text {c．}}$ | Tomel Contel ratio | ${ }^{124220}$ | ${ }^{12,480}$ | ${ }^{12585}$ | 1，989\％ | ${ }^{1227 \%}$ | ${ }^{12515}$ | n， 1.85 | $\mathrm{c}_{3}(5)$ |  |
|  | － |  |  | ${ }^{30}$ | ${ }^{39}$ | ${ }^{3}$ | ${ }^{0}$ | ${ }^{20}$ | ${ }^{28}$ |  |  |
| Memorandum tems | ： | Temen |  | 。 | 。 | 。 | 。 | － | － |  |  |
|  | F | Total Additional Tier 1 and Tier 2 instruments eligible as regulatory capital under the CRR provisions that convert into Common Equity Tier 1 or are written down upon a trigger event（2） |  |  |  |  | － | － | － |  |  |
|  | ${ }^{\text {r．}} 1$ | Of which：eligible instruments whose trigger is above CET1 capital ratio in the dverse scenario（2） |  |  |  |  | － | － | － |  |  |
|  | － |  |  |  |  | 14，996 |  |  | ${ }^{1.3850}$ |  |  |



## 2014 EU-wide Stress Test - Restructuring scenarios

| (min EUR) | Effects of mandatory restructuring plans publicly announced before 31st December 2013 and formally agreed with the European Commission. |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Baseline scenario |  | Adverse scenario |  | Narrative description of the transactions. (type, date of completion/commitment, portfolios, subsidiaries, branches) |
|  | CET1 impact | Risk exposure amount impact | CET1 impact | Risk exposure amount impact |  |
| 2013 | 0 | 0 |  |  |  |
| 2014 | 0 | 0 | 0 | 0 |  |
| 2015 | 0 | 0 | 0 | 0 |  |
| 2016 | 0 | 0 | 0 | 0 |  |
| Total | 0 | 0 | 0 | 0 |  |

## 2014 EU-wide Stress Test

Outcome of the Stress Test based on the Restructuring plan for banks whose plan was formally agreed with the European Commission after 31 December 2013


## 2014 EU-wide Stress Test

Major Capital Measures from 1 January to 30 September 2014
Major Capital Measures Impacting Tier 1 and Tier 2 Eligible Capital from 1 January 2014 to 30 September 2014

| Issuance of CET 1 Instruments | Impact on Common <br> Equity Tier $\mathbf{1}$ <br> Million EUR |
| :--- | :---: |
| Raising of capital instruments eligible as CET1 capital (+) | 0 |
| Repayment of CET1 capital, buybacks ( - ) | 0 |
| Conversion to CET1 of hybrid instruments becoming effective between 1 January and 30 September 2014 (+) | 0 |


| Net issuance of Additional Tier $\mathbf{1}$ and T2 Instruments | Impact on Additional <br> Tier $\mathbf{1}$ and Tier $\mathbf{2}$ <br> Million EUR |
| :--- | :---: |
| Net issuance of Additional Tier 1 and T2 Instruments with a trigger at or above bank's post stress test CET1 ratio in the adverse <br> scenario during the stress test horizon $(+/-)$ | 0 |
| Net issuance of Additional Tier 1 and T2 Instrument with a trigger below bank's post stress test CET1 ratio in the adverse scenario <br> during the stress test horizon $(+/-)$ | 0 |


| Losses |  |
| :--- | :---: |
| Realized fines/litigation costs from 1 January to 30 September 2014 (net of provisions) (-) | 0 |
| Other material losses and provisions from 1 January to 30 September $2014(-)$ | 0 |

